This is a plain language summary of a clinical research study. The study waslooking the effects of a drug called anamorelin for Japanese people withadvanced non-small cell lung cancer (often shortened to NSCLC) who alsohad a condition called cachexia. People with cachexia have a loss of appetite,severe weight loss, loss of body fat and loss of muscle mass (called musclewasting). Cachexia is common in many chronic (long term) diseases, such ascancer and can lead to a decrease in a person's ability to do everyday tasks(called functional strength). Cachexia can negatively affect a person's qualityof life and increases the risk of serious side effects during chemotherapy.Anamorelin is a drug that has been shown in previous research studies to improve appetite and increase lean body mass(the total weight of the body, not counting fat) and overall body weight. In this study, participants were given anamorelin(100 mg daily) for 12 weeks.This Plain Language Summary of Publication article (PLSP) from Future Oncology summarises the results of a study that looked at the effect of a medication called anamorelin in the treatment of Japanese people with advanced non-small cell lung cancer (NSCLC) and cachexia. Individuals with cachexia have a loss of appetite, severe weight loss, and loss of body fat and muscle mass. Cachexia is common in many long-term diseases such as cancer and can reduce the person’s ability to carry out everyday tasks, reduce their quality of life, and also increase the risk of serious side effects during chemotherapy.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Anamorelin (ONO-7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)’ that was published in Cancer. 

Visit the American Cancer Society Journals website using the link to read the article.